Scope
Reference
DACPM2025-41
Description
Procurement of Ravulizumab IV Infusion.
Contract 1. Ravulizumab IV Infusion
Supplier
Contract value
- £1,200,000 excluding VAT
- £1,200,000 including VAT
Above the relevant threshold
Award decision date
24 September 2025
Standstill period
- End: 3 October 2025
- 8 working days
Earliest date the contract will be signed
4 October 2025
Contract dates (estimated)
- 4 October 2025 to 30 September 2027
- 1 year, 11 months, 28 days
Main procurement category
Goods
CPV classifications
- 33600000 - Pharmaceutical products
Contract locations
- UKN - Northern Ireland
Procedure
Procedure type
Direct award
Supplier
ALEXION PHARMA UK LIMITED
- Companies House: 05970106
- Public Procurement Organisation Number: PQTX-1761-VLYY
1 Francis Crick Avenue
Cambridge
CB2 0AA
United Kingdom
Email: UKMarketAccess@alexion.com
Region: UKH12 - Cambridgeshire CC
Small or medium-sized enterprise (SME): No
Voluntary, community or social enterprise (VCSE): No
Supported employment provider: No
Public service mutual: No
Contract 1. Ravulizumab IV Infusion
Contracting authority
Belfast Health & Social Care Trust
- Public Procurement Organisation Number: PLQJ-5727-JCLR
Trust Headquarters, 2nd Floor, Non Clinical Support Building, Royal Victoria Hospital
Belfast
BT12 6BA
United Kingdom
Region: UKN06 - Belfast
Organisation type: Public authority - central government
Devolved regulations that apply: Northern Ireland